Document is current
Any future updates will be listed below
-
Authors
Jensen, Kristian Høj Reveles
Dam, Vibeke H.
Ganz, Melanie
Fisher, Patrick MacDonald
Ip, Cheng-Teng
Sankar, Anjali
Marstrand-Joergensen, Maja Rou
Ozenne, Brice
Osler, Merete
Penninx, Brenda W. J. H.
Pinborg, Lars H.
Frokjaer, Vibe Gedsø
Knudsen, Gitte Moos
Jørgensen, Martin Balslev https://orcid.org/0000-0002-1321-8901
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R279–2018–1145, R279–2018–1145)
Research Fund of the Mental Health Services - Capital Region of Denmark
- License Information
-
More Information
Article History
Received: 12 November 2022
Accepted: 19 February 2023
First Online: 9 March 2023
Declarations
:
: The study is conducted according to the principles of the seventh revision of the Declaration of Helsinki (2013) and was reviewed and approved by the Committees on Health Research Ethics in the Capital Region of Denmark (reference number: H-20083013). Before undertaking any study-related procedures, each participant receives verbal and written explanations of study aims, methods, potential hazards, and benefits from investigators and provides written informed consent. The study will be carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: GMK has received honoraria as speaker for SAGE Therapeutics/Biogen and H. Lundbeck and as advisor for Sanos, and VF as a consultant for SAGE Therapeutics. MJ and VF have given talks sponsored by Lundbeck Pharma and MJ for Boehringer Ingelheim. The remaining authors declare that the research is conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. MRMJ received sponsorship from Jazz Pharmaceuticals for attendance at the 14th European Epilepsy Congress.
